Matches in Ubergraph for { <http://purl.obolibrary.org/obo/NCIT_C172616> ?p ?o ?g. }
Showing items 1 to 32 of
32
with 100 items per page.
- NCIT_C172616 IAO_0000115 "A highly soluble small molecule calcitonin gene related peptide (CGRP) receptor antagonist, with potential analgesic and immunomodulating activities. Upon administration, zavegepant targets, binds to and inhibits the activity of CGRP receptors located on mast cells in the brain. This may inhibit neurogenic inflammation caused by trigeminal nerve release of CGRP. In addition, by blocking the CGRP receptors located in smooth muscle cells within vessel walls, zavegepant inhibits the pathologic dilation of intracranial arteries. Zavegepant, by blocking the CGRP receptors, also suppresses the transmission of pain by inhibiting the central relay of pain signals from the trigeminal nerve to the caudal trigeminal nucleus. Altogether, this may relieve migraine. As CGRP receptors induce the release of pro-inflammatory mediators, such as interleukin-6 (IL-6), from inflammatory cells, zavegepant may prevent an IL-6-mediated inflammatory response. Zavegepant may also inhibit the CGRP-mediated induction of eosinophil migration and the stimulation of beta-integrin-mediated T cell adhesion to fibronectin at the site of inflammation, and may abrogate the CGRP-mediated polarization of the T cell response towards the pro-inflammatory state characterized by Th17 and IL-17. This may improve lung inflammation and oxygenation, prevent edema, and further lung injury. CGRP, a 37 amino-acid peptide expressed in and released from a subset of polymodal primary sensory neurons of the trigeminal ganglion and nerve fibers projecting to the airways and by pulmonary neuroendocrine cells, plays an important role in pain transmission, inflammation, and neurogenic vasodilatation. It is released upon acute lung injury and upregulation of transient receptor potential (TRP) channels." @default.
- NCIT_C172616 NCIT_NHC0 "C172616" @default.
- NCIT_C172616 NCIT_P106 "Pharmacologic Substance" @default.
- NCIT_C172616 NCIT_P108 "Zavegepant" @default.
- NCIT_C172616 NCIT_P208 "CL1406705" @default.
- NCIT_C172616 NCIT_P210 "1337918-83-8" @default.
- NCIT_C172616 NCIT_P319 "ODU3ZAZ94J" @default.
- NCIT_C172616 NCIT_P322 "FDA" @default.
- NCIT_C172616 normalizedInformationContent "100" @default.
- NCIT_C172616 referenceCount "1" @default.
- NCIT_C172616 hasExactSynonym "1-Piperidinecarboxamide, 4-(1,2-Dihydro-2-oxo-3-quinolinyl)-N-((1R)-1-((7-methyl-1H-indazol-5-yl)methyl)-2-(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl)-" @default.
- NCIT_C172616 hasExactSynonym "4-(1,2-Dihydro-2-oxo-3-quinolinyl)-N-((1R)-1-((7-methyl-1H-indazol-5-yl)methyl)-2-(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl)-1-piperidinecarboxamide" @default.
- NCIT_C172616 hasExactSynonym "BHV 3500" @default.
- NCIT_C172616 hasExactSynonym "BHV-3500" @default.
- NCIT_C172616 hasExactSynonym "BHV3500" @default.
- NCIT_C172616 hasExactSynonym "BMS 742413" @default.
- NCIT_C172616 hasExactSynonym "BMS-742413" @default.
- NCIT_C172616 hasExactSynonym "BMS742413" @default.
- NCIT_C172616 hasExactSynonym "Vazegepant" @default.
- NCIT_C172616 hasExactSynonym "ZAVEGEPANT" @default.
- NCIT_C172616 hasExactSynonym "Zavegepant" @default.
- NCIT_C172616 inSubset NCIT_C173381 @default.
- NCIT_C172616 inSubset NCIT_C173383 @default.
- NCIT_C172616 inSubset NCIT_C63923 @default.
- NCIT_C172616 type Class @default.
- NCIT_C172616 isDefinedBy ncit.owl @default.
- NCIT_C172616 label "Zavegepant" @default.
- NCIT_C172616 subClassOf NCIT_C172616 @default.
- NCIT_C172616 subClassOf NCIT_C1908 @default.
- NCIT_C172616 subClassOf NCIT_C1909 @default.
- NCIT_C172616 subClassOf NCIT_C241 @default.
- NCIT_C172616 subClassOf NCIT_C78272 @default.